Latest Safety News

Belararox Limited has commenced a significant diamond drilling campaign at its TMT Project in Argentina, supported by a recent A$8.88 million capital raise that underpins its 2025 exploration programs across Argentina and Botswana.

Acusensus has secured major contract expansions across Australia and New Zealand, driving a 15.8% revenue increase in Q2 FY25 and bolstering its cash reserves to $30.3 million. The company’s strategic international push and innovative enforcement technologies position it for sustained growth.

Adriatic Metals has transitioned from development to production, delivering strong silver equivalent output in Q4 2024 despite extreme weather disruptions, and has updated its 2025 guidance with ambitious expansion plans.

Enterprise Metals Limited has secured a heritage agreement and government grant to progress drilling at its Doolgunna Project, while also navigating key board appointments and capital raises in the December 2024 quarter.

Energy Transition Minerals Ltd renews focus on its Greenland rare earths project while navigating arbitration and legal challenges, alongside ongoing lithium exploration in Canada and Spain.

Grange Resources delivered a robust December quarter with increased pellet and concentrate output, a stronger cash position, and key advancements in its North Pit Underground Project.

Southern Cross Gold Consolidated Ltd. reported a significantly reduced net loss of $2.41 million for Q2 2024, down from $43.69 million a year earlier, as it sharpens focus on its Australian gold projects following a major corporate restructuring.

Belararox Limited has validated the presence of a copper porphyry system at its Malambo prospect in Argentina through recent geophysical surveys, setting the stage for an imminent drilling campaign.

Alpha HPA Limited has reached a major funding milestone with a $400 million senior debt package for its HPA First Project Stage 2, while experiencing accelerating demand from the semiconductor sector and advancing new product developments.

Neurotech International reports key clinical progress in paediatric neurological disorders, securing FDA orphan drug designation for its Rett Syndrome treatment and advancing pivotal trials for ASD and PANDAS/PANS.

PYC Therapeutics reports substantial progress across all four of its drug development programs in Q4 2024, including key regulatory designations and clinical milestones that set the stage for pivotal trials in 2025.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.